Presentation: Conformity assessment evidence
Download as PPTX, PDF1 like1,365 views
The document presents an overview of conformity assessment in medical devices, explaining its significance in determining the safety and performance compliance of devices as per regulatory authority standards. Key changes in regulatory frameworks, particularly aligning Australian regulations with new EU medical device regulations, are discussed, emphasizing essential principles for safety, design, and manufacturing of medical devices. The document also highlights forthcoming shifts in compliance requirements and the importance of thorough preparation and documentation in the assessment process.
Presentation: Conformity assessment evidence
- 1. Conformity Assessment Evidence A Regulator’s Perspective Dr Elizabeth McGrath Medical Devices Branch Medical Devices and Product Quality, TGA 2017 ARCS Annual Conference
- 2. Presentation Overview Definition & Important Concepts The Evidence Change is Coming Conformity Assessment Evidence 2
- 3. What is Conformity Assessment? Conformity Assessment: The systematic examination of evidence generated and procedures undertaken by the manufacturer, under requirements established by the Regulatory Authority, to determine that a medical device is safe and performs as intended by the manufacturer and, therefore, conforms to the Essential Principles of Safety and Performance for Medical Devices. - GHTF Conformity Assessment Evidence 3
- 4. What is Conformity Assessment? • All Devices, unless exempt, Must Undergo Conformity Assessment according to their risk classification. • All Devices must comply with the applicable essential principles. Conformity Assessment Evidence 4
- 5. Important Concept 1 “Begin at the beginning,” the King said, very gravely, “and go on till you come to the end, then stop.” - Lewis Carroll Regula tor Conformity Assessment Evidence 5
- 6. Important Concept 1 (continued) DEVICE LIFECYCLE Conformity Assessment Evidence 6
- 7. Important Concept 2 PREPARATION PREPARATION PREPARATION Conformity Assessment Evidence 7
- 8. The Evidence Conformity Assessment Evidence 8
- 9. The Essential Principles • Schedule 1 – Medical Devices Regulations • Set out requirements relating to the safety and performance of the medical device Conformity Assessment Evidence 9
- 10. Essential principles for safety and performance 1. Use of medical devices not to compromise health and safety 2. Design and construction of medical devices to conform to safety principles 3. Medical devices to be suitable for intended purpose General principles Conformity Assessment Evidence 10
- 11. Essential principles for safety and performance 4. Long-term safety 5. Medical devices not to be adversely affected by transport or storage 6. Benefits of medical devices to outweigh any side effects General principles Conformity Assessment Evidence 11
- 12. Essential principles for safety and performance 7. Chemical, physical and biological properties 8. Infection and microbial contamination 9. Construction and environmental properties 10.Medical devices with a measuring function 11.Protection against radiation Principles about design and construction Conformity Assessment Evidence 12
- 13. Essential principles for safety and performance 12. Medical devices connected to or equipped with an energy source 13. Information to be provided with medical devices 14. Clinical evidence 15. Principles applying to IVD medical devices only Principles about design and construction Conformity Assessment Evidence 13
- 16. Format • Should be easy to understand/find where information is located! • Documents should be searchable • Guidance on structuring a submission – The IMDRF Table of Contents documents (on TGA website) Conformity Assessment Evidence 16
- 17. Changes are on the way Conformity Assessment Evidence 17
- 18. EU Regulatory Requirements The new Regulations on medical devices On 5 April 2017, 2 new Regulations on medical devices were adopted. These replace the existing Directives. • Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC • Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC Commission Decision 2010/227/EU The new rules will only apply after a transitional period. Namely, 3 years after entry into force for the Regulation on medical devices (spring 2020) and 5 years after entry into force (spring 2022) for the Regulation on in vitro diagnostic medical devices. Conformity Assessment Evidence 18
- 19. The Expert Panel Review of Medicines and Medical Devices regulation • Two reports on medicines and devices and complementary medicines and advertising released during 2015 • Review process included discussion papers, submissions and interviews with key stakeholders. Followed by stakeholder workshops and other meetings to get feedback • Department considered stakeholder feedback and advised Minister, who took her preferred position to Cabinet • Government intent released in May 2016 budget, and full response released on 15 September 2016 Conformity Assessment Evidence 19
- 20. Recommendation 20 – Continue to Align with the EU • Australian regulation of medical devices is, wherever possible, aligned with the European framework, • Where there are Australian specific requirements, there must be a clear rationale for this − Classification, EPs, CA Procedures, Definitions, etc. Conformity Assessment Evidence 20
- 21. Implementation and Governance • A broad plan for implementation over 2-3 years agreed by Government • We will also consult closely with stakeholders in developing the finer detail on implementation, including assessment of regulatory impacts and fees and charges • TGA has been empowered to work out much of the detail on how specific changes could be implemented – But we will need to go back to government for approval, in particular where changes to the TGA Act or Regulations are needed Conformity Assessment Evidence 21
- 22. Aligning the EPs and GSPRs • Annex 1 of the new EU regulations • Includes 23 ‘General Safety and Performance Requirements’ (GSPR) replacing ‘Essential Requirements’ • Based on the GHTF Essential Principles 2012 Conformity Assessment Evidence 22
- 23. GSPR Chapter I General Requirements – GSPRs 1 - 9 • Key changes: − Major changes regarding risk management (GSPRs 2 – 5) • Closely aligned with ISO: 14971; • GSPR 3 – Continuous Risk Management processes; • GSPR 4 – Sequence of risk control procedures; • GSPR 5 – Risk regarding usability – ergonomics, training, intended user. − GSPR 9: Minimise risks for non-therapeutic devices (aesthetic, etc.) Conformity Assessment Evidence 23
- 24. GSPR Chapter II Requirements Regarding Design and Manufacture – GSPR 10 - 22 GSPR 10 Substances: Justification for CMR or endocrine-disrupting substances, when present > 0.1% (w/w); Guidelines on phthalates; Labelling requirement on devices and packaging for above substances. – Reduce risks linked to the size and properties of particles released into patient’s or use’s body, particularly nanomaterials. Conformity Assessment Evidence 24
- 25. GSPR Chapter II Requirements Regarding Design and Manufacture – GSPR 10 - 22 • GSPR 11 – Infection and microbial contamination – Reduce risks from unintended cuts and pricks; – Design to facilitate safe cleaning, disinfection and/or re-sterilisation; • GSPR 12 – Devices incorporating a substance considered to be a medicinal product and devices that are composed of substances or of combination of substance that are absorbed by or locally dispersed in the human body – Verified with the specified requirements laid down in Directive 2001/83/EC; – Evaluation of ADME profile, local tolerance, toxicity, interaction with other devices. Conformity Assessment Evidence 25
- 26. Chapter II Requirements Regarding Design and Manufacture – GSPR 10 - 22 • GSPR 14 – Construction of Devices and Interaction with Environment – designed and manufactured in such a way that adjustment, calibration, and maintenance can be done safely and effectively. – be designed and manufactured in such a way as to facilitate their safe disposal and the safe disposal of related waste substances by the user, patient or other person. – manufacturers shall identify and test procedures and measures as a result of which their devices can be safely disposed after use. Such procedures shall be described in the instructions for use. Conformity Assessment Evidence 26
- 27. GSPR Chapter II Requirements Regarding Design and Manufacture – GSPR 10 - 22 • GSPR 17 - Software – Key changes: software shall be developed and manufactured in accordance with the state of the art taking into account the principles of development life cycle, risk management, including information security, verification and validation. requirements for software and mobile computing platforms – considerations for size and contrast ratio of screen, level of light and noise in environment. minimum hardware requirements, IT network characteristics, IT security measures. Conformity Assessment Evidence 27
- 28. GSPR Chapter II Requirements Regarding Design and Manufacture – GSPR 10 - 22 • GSPR 18 - Active devices and devices connected to them – Key improvements: Immunity to electromagnetic interference; • (EP 12.5 – only minimise electromagnetic field generation) Protect, as far as possible, against unauthorised access that could hamper the device from functioning as intended Conformity Assessment Evidence 28
- 29. GSPR Chapter II Requirements Regarding Design and Manufacture – GSPR 10 - 22 • GSPR 19 - Particular requirements for active implantable devices – minimise risks connected with medical treatment, in particular those resulting from the use of defibrillators or high- frequency surgical equipment. – minimise risks which may arise where maintenance and calibration are impossible, including: excessive increase of leakage currents, ageing of the materials used, excess heat generated by the device, decreased accuracy of any measuring or control mechanism. Conformity Assessment Evidence 29
- 30. GSPR Chapter II Requirements Regarding Design and Manufacture – GSPR 10 - 22 • GSPR 22 – Protection against the risks posed by medical devices intended by the manufacturer for use by lay persons (no requirement in current EPs) − Important for home use devices,; − Safety, performance, design and manufacture considering the skills and means available to the lay person, easy to understand information. Conformity Assessment Evidence 30
- 31. GSPR Chapter III Requirements Regarding Information Supplied with the Device – GSPR 23 • GSPR 23 – Information supplied by the manufacturer – Numerous Changes, Including – a requirement for UDI – in the case of implantable devices, the overall qualitative and quantitative information on the materials and substances to which patients can be exposed; – a notice to the user and/or patient that any serious incident that has occurred in relation to the device should be reported to the manufacturer and the competent authority of the Member State in which the user and/or patient is established; – Implant card and information/warnings for patients Conformity Assessment Evidence
- 32. Work has already begun… https://www.tga.gov.au/consultation/consultation-alignment-european-medical-device-regulatory-framework Conformity Assessment Evidence 32
Editor's Notes
- #4: In a nut shell, conformity assessment in this context refers to the procedures used and evidence generated by the manufacturer to demonstrate that a medical device is safe, fit for purpose and performs as intended.
- #11: Closely aligned with ‘Essential Requirements’ with only minor differences
- #12: Closely aligned with ‘Essential Requirements’ with only minor differences